A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.
To evaluate the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR based on Independent Review Committee (IRC) assessment of progression-free survival (PFS) per the Lugano Classification for Non-Hodgkin Lymphoma (NHL) in subjects with previously untreated mantle cell lymphoma (MCL).
Inclusion Criteria:
Exclusion Criteria:
Caba, C1118AAT, Argentina
So Paulo, 08270-070, Brazil
Gongshu District, 310022, China
Haidian District, 100191, China
Tianjian, 300020, China
Wuhou District, 610041, China
Xicheng District, 100050, China
Xuhui District, 200032, China
Ostrava Poruba, 708 52, Czechia
Nordrhein-Westfalen, 52064, DE, Germany
Rheinland-Pfalz, 55131, DE, Germany
Woj. Podkarpackie, 36-200, Poland